The dry eye syndrome treatment market is projected to grow from USD 5.8 billion in 2025 to USD 10.8 billion by 2035, at a CAGR of 6.4%. Artificial Tears will dominate with a 36.4% market share, while rx will lead the prescription segment with a 58.7% share.